Abstract: Retinal neovascularization is a type of ophthalmic disease that involves abnormal proliferation of retinal and choroidal blood vessels. Vascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of fundus neovascular diseases. Anti-VEGF drugs (such as pegatinib, bevacizumab, ranibizumab, busizumab, aflibercept, conbercept, fariximab, etc) can reduce vascular leakage, promote the absorption of effusion and accelerate the regression of neovascularization. Neovascular diseases in the fundus are related to multiple factors, and targeting multiple channels simultaneously may produce better prognosis. With the development of new drug delivery methods, sustained-release drugs, and novel drugs targeting more pathways, anti VEGF drugs provide a more efficient and safe option for the treatment of retinal neovascularization. Innovative drugs include gene therapy drugs ADVM-022 and RGX-314, local eye drops such as pazopanib, squalylamine, regorafenib, oral tyrosine kinase inhibitor CM082, and monoclonal antibody drug loaded implants , all of which have certain prospects.(Int Rev Ophthalmol, 2024, 48:  464-470)

Key words: vascular endothelial growth factor, fundus neovascular disease, anti-VEGF drug